Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:08158's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.3 * Ranked among companies with meaningful Forward Dividend Yield % only.
China Regenerative Medicine International (HKSE:08158) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
China Regenerative Medicine International Forward Dividend Yield % Related Terms
HKSE:08158 vs VRTX, REGN, RVMD: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, China Regenerative Medicine International's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Regenerative Medicine International Forward Dividend Yield % vs Biotechnology Industry
What does a Forward Dividend Yield % of 0.00% mean?
China Regenerative Medicine International (HKSE:08158) has a Forward Dividend Yield % of 0.00% as of Aug. 08, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on China Regenerative Medicine International and its competitors. According to the industry distribution chart, China Regenerative Medicine International ranks #999999 out of 149 companies in the Biotechnology industry.
Is China Regenerative Medicine International's Forward Dividend Yield % too high?
China Regenerative Medicine International's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, China Regenerative Medicine International ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, China Regenerative Medicine International has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does China Regenerative Medicine International's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, China Regenerative Medicine International ranks #999999 out of 149 companies for Forward Dividend Yield %. This places China Regenerative Medicine International in the lower half of its industry. The industry median Forward Dividend Yield % is 1.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.30, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on China Regenerative Medicine International and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Regenerative Medicine International's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Regenerative Medicine International stock overvalued right now?
Based on GuruFocus' analysis, China Regenerative Medicine International (HKSE:08158) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.63, compared to a current price of HK$0.23 — trading 63.2% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. China Regenerative Medicine International's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For China Regenerative Medicine International (HKSE:08158), the current Forward Dividend Yield % is 0.00% as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Regenerative Medicine International (HKSE:08158) Overvalued in 2026?
Based on GuruFocus' analysis, China Regenerative Medicine International stock appears to be undervalued.
The current stock price of HK$0.23 is trading 63.2% below its estimated GF Value™ of HK$0.63.
GuruFocus considers China Regenerative Medicine International to be Possible Value Trap.
Key valuation signals for HKSE:08158:
Forward Dividend Yield %: 0.00%
GF Value™: HK$0.63 vs. price of HK$0.23 (63.2% below fair value)
No single metric tells the full story. See the HKSE:08158 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Regenerative Medicine International Ltd is an investment holding company. The company is engaged in the provision of healthcare products and services. It is engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of company includes tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and other business division. The segments of the company are Aesthetic medical and beauty services and Medical services. The majority of the company's revenue is derived from its Aesthetic medical and beauty services segment that provides medical beauty products and services. Geographically, the Hong Kong accounts for the majority of the revenue and also has a presence in PRC.
30GF Score
Get the complete analysis for HKSE:08158
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08158 has been successfully added to your 
